EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929

Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, Carl M Gay, Lauren A Byers, Ying-Qi Zhao, Mary W Redman, Daniel R Carrizosa, Wei-Lien Wang, William J Petty, Kathan Mehta, Bryan A Faller und 8 weitere

Journal of Thoracic Oncology · 2025-03 · 20 (3) · 383-394

DOI: 10.1016/j.jtho.2024.10.021 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Thoracic Oncology, 2025-03. Verfasst von Nagla Abdel Karim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Inova Schar Cancer Institute, Fairfax, Virginia; University of Virginia, Fairfax, Virginia. Electronic address: nagla.karim5@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms, Nuclear Proteins. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genentech, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate whether the addition of a poly (adenosine diphosphate-ribose) polymerase inhibitor talazoparib to maintenance immune checkpoint inhibitor atezolizumab after frontline chemoimmunotherapy improved outcomes in patients with Schlafen 11 (SLFN11)-positive extensive-stage SCLC (ES-SCLC). METHODS: Patients with newly diagnosed SLFN11 expressing (H-score ≥ 1, evaluated centrally) ES-SCLC were randomized to maintenance atezolizumab (A) versus atezolizumab plus talazoparib (AT) after frontline chemotherapy plus atezolizumab. The primary objective was to compare progression-free survival (PFS) using a one-sided 10% level stratified log-rank test. Secondary endpoints included objective response rate, overall survival, and toxicity. The target sample size was 84 eligible patients. RESULTS: From June 15, 2020, to December 15, 2022, 106 eligible patients were randomized (54 to AT and 52 to A). Progression-free survival was improved with AT versus A (hazard ratio = 0.66, 80% confidence interval: 0.50-0.86, one-sided p = 0.019) with a median PFS of 2.9 and 2.4 months; overall survival was not different between groups (hazard ratio = 0.98, 80% confidence interval: 0.71-1.36, one-sided p = 0.47). Grade 3 and higher non-hematologic treatment-related adverse events occurred in 17% of patients with AT and 14% of patients with A. Grade 3 and higher hematological treatment-related adverse events were more common in AT (50%) than in A (4%) (p < 0.001). CONCLUSION: Maintenance AT improved PFS in patients with SLFN11-positive ES-SCLC that did not progress after initial chemo-immunotherapy. Hematologic toxicity, primarily grade 3 anemia, was increased with AT, as expected. Prospective biomarker selection was demonstrated, paving the way for future evaluation of novel therapies in molecularly defined SCLC populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsNuclear ProteinsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingSurvival RatePhthalazines

Stichwörter der Autor:innen

MaintenancePARP inhibitorsSLFN11Small Cell Lung Cancer

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabNuclear ProteinsSLFN11 protein, humantalazoparibPhthalazines

Autor:innen und Institutionen

  • Inova Schar Cancer Institute, Fairfax, Virginia; University of Virginia, Fairfax, Virginia. Electronic address: nagla.karim5@gmail.com.
  • SWOG Statistical Center and Data Management Center, Seattle, Washington; Fred Hutchinson Cancer Center, Seattle, Washington.
  • Cedars-Sinai Medical Center, Los Angeles, California; Department of Thoracic Head and Neck Medical Oncology, The University of Texas Maryland.
  • Anderson Cancer Center, Houston, Texas.
  • Levine Cancer Institute, Charlotte, North Carolina.
  • Department of Pathology, MD Anderson Cancer Center, The University of Texas Houston, Texas.

Förderung

  • NCI NIH HHS
  • Genentech
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Karim, N. A., Miao, J., Reckamp, K. L., Gay, C. M., Byers, L. A., Zhao, Y. Q., Redman, M. W., Carrizosa, D. R., Wang, W. L., Petty, W. J., Mehta, K., Faller, B. A., Agamah, E. S., Kasbari, S. S., Malisetti, R. K., Kumar, A., Schallenkamp, J., Alluri, K. C., Gray, J. E., & Kelly, K. (2025). Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. Journal of Thoracic Oncology, 20(3), 383-394. https://doi.org/10.1016/j.jtho.2024.10.021

Vancouver

Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, et al. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. Journal of Thoracic Oncology. 2025;20(3):383-394. doi:10.1016/j.jtho.2024.10.021

BibTeX
@article{Karim2025,
  author = {Karim, Nagla Abdel and Miao, Jieling and Reckamp, Karen L and Gay, Carl M and Byers, Lauren A and Zhao, Ying-Qi and Redman, Mary W and Carrizosa, Daniel R and Wang, Wei-Lien and Petty, William J and Mehta, Kathan and Faller, Bryan A and Agamah, Edem S and Kasbari, Samer S and Malisetti, Rajini K and Kumar, Atul and Schallenkamp, John and Alluri, Krishna C and Gray, Jhanelle E and Kelly, Karen},
  title = {Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929},
  journal = {Journal of Thoracic Oncology},
  year = {2025},
  volume = {20},
  number = {3},
  pages = {383--394},
  doi = {10.1016/j.jtho.2024.10.021}
}
Kostenlos starten →